Clinical research trial for evaluating different properties, such as safety, tolerability and body interaction, of a new drug called ALY688ER, administered as subcutaneous injection in healthy overweight or obese people.
Researchers are looking for healthy adult volunteers, aged 18 and over, who are overweight or obese, to take part in a new medical study. The study aims to test a new medicine called ALY688ER, which is a potential treatment for a liver condition called NASH (Non-alcoholic steatohepatitis) – a serious type of fatty liver disease. This is one of the first times this medicine will be given to people. The main goal is to check how safe it is and how the body reacts to it when given as an injection under the skin. By understanding these early effects, scientists can decide if it's safe to continue testing the medicine in larger studies for people who actually have NASH.
At a glance
What is this study about?
This study is about a new medicine, ALY688ER, which doctors hope could one day treat a liver condition called NASH. NASH stands for Non-alcoholic steatohepatitis. It's a serious type of fatty liver disease that isn't caused by drinking too much alcohol. It can lead to severe liver problems over time if not managed. Currently, there aren't many specific medicines for NASH, so finding new treatments is very important.
This specific study is called a 'Phase I' trial. This means it's one of the very first times this new medicine, ALY688ER, is being given to people. The main purpose of this early stage isn't to see if it cures NASH yet, but to carefully check a few key things. Researchers want to make sure the medicine is safe, see how well the body can cope with it (we call this 'tolerability'), and understand how the body uses and processes the medicine after it's injected under the skin.
By carefully studying healthy volunteers first, scientists can gather important information. This helps them understand if the medicine has any unexpected side effects and how much of it the body needs to absorb to potentially work. This vital information will then guide them on whether it's safe to move forward with more extensive studies involving people who actually have NASH, to see if the medicine can help them feel better or improve their liver health.
Key takeaways
- This is an early study of a new medicine (ALY688ER) for fatty liver disease (NASH).
- It aims to check the medicine's safety and how the body handles it.
- Healthy overweight or obese adults (18+) are needed.
- The medicine is given by injection under the skin.
- Taking part helps advance medical research, but direct health benefits are not expected for volunteers.
- Close medical monitoring will happen throughout the study.
Who may be eligible?
To be considered for this study, you need to be an adult, 18 years old or older. There is no upper age limit, which means people of all adult ages can take part. Both men and women are welcome to apply.
Crucially, you should be a healthy individual who is either overweight or obese. This means your body mass index (BMI) would be in a certain range, which the study staff will check. Even though the medicine is being developed for a liver condition, this first-stage study is looking for healthy people to understand the medicine's basic effects without other health issues getting in the way.
There will be other detailed health checks and requirements that the study team will go through with you. These checks are put in place to ensure your safety throughout the study and that the results they get are as clear as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you generally healthy?
- Are you considered overweight or obese?
- Are you comfortable with receiving injections under the skin?
- Are you able to commit to several study visits and possibly overnight stays?
What does participation involve?
If you decide to take part, you'll be given the new medicine, ALY688ER, as an injection under your skin. The study team will explain exactly how and when this will happen. You can expect to have a number of visits to the study clinic, which might include overnight stays, so doctors can carefully monitor you. During these visits, you'll have various check-ups. This could involve having your blood taken, measuring your heart rate and blood pressure, and answering questions about how you're feeling.
These assessments are important for the researchers to understand how your body is reacting to the medicine, to check for any side effects, and to see how the medicine is processed by your body. The total length of your involvement in the study will be explained in detail before you agree to take part, including the time for follow-up appointments after you've received the medicine.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is NASH?
NASH (Non-alcoholic steatohepatitis) is a serious form of fatty liver disease not caused by alcohol. It can lead to liver damage over time.
Why are healthy people needed for a study about a liver disease?
This is a very early study. We need healthy volunteers first to safely understand how the medicine behaves in the body and if there are any immediate side effects, before testing it in patients with the disease.
How will the medicine be given?
The new medicine, ALY688ER, will be given as an injection under the skin, similar to an insulin shot.
Will I get paid for taking part?
The study team will provide information about any compensation for your time and travel, which varies for each study.
What if I change my mind?
You have the right to leave the study at any time, for any reason, without affecting your current or future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.